Insys Therapeutics Inc  

(Public, NASDAQ:INSY)   Watch this stock  
Find more results for INSY
8.99
0.00 (0.00%)
Jan 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.10 - 15.02
Open     -
Vol / Avg. 0.00/2.39M
Mkt cap 659.12M
P/E     -
Div/yield     -
EPS -2.55
Shares 73.32M
Beta 0.76
Inst. own 30%
Apr 2, 2018
Q4 2017 INSYS Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jan 11, 2018
INSYS Therapeutics Inc at JPMorgan Healthcare Conference - Webcast
Nov 29, 2017
INSYS Therapeutics Inc at Piper Jaffray Healthcare Conference
Nov 2, 2017
Q3 2017 INSYS Therapeutics Inc Earnings Release
Nov 2, 2017
Q3 2017 INSYS Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -542.29% 3.13%
Operating margin -573.01% 3.02%
EBITD margin - 7.21%
Return on average assets -201.94% 2.15%
Return on average equity -358.28% 2.91%
Employees 423 -
CDP Score - -

Address

10220 S 51st St Ste 2
PHOENIX, AZ 85044-5231
United States - Map
+1-602-9102617 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Officers and directors

Steven J. Meyer Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Saeed Motahari President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Andrew G. Long Chief Financial Officer
Bio & Compensation  - Reuters
Venkat R. Goskonda Senior Vice President - Research & Development
Bio & Compensation  - Reuters
Steve Sherman Senior Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Franc Del Fosse General Counsel, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Rohit Vishnoi Director
Bio & Compensation  - Reuters
Pierre Lapalme Independent Director
Age: 76
Bio & Compensation  - Reuters
Brian Tambi Independent Director
Age: 71
Bio & Compensation  - Reuters